CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $372,000 | +4.5% | 5,700 | -2.6% | 0.02% | +4.5% |
| Q2 2022 | $356,000 | -3.3% | 5,850 | -0.2% | 0.02% | +46.7% |
| Q1 2022 | $368,000 | -22.7% | 5,860 | -6.6% | 0.02% | -11.8% |
| Q4 2021 | $476,000 | -41.5% | 6,275 | -13.7% | 0.02% | -46.9% |
| Q3 2021 | $814,000 | -58.2% | 7,275 | -39.5% | 0.03% | -57.9% |
| Q2 2021 | $1,947,000 | +114.4% | 12,025 | +61.4% | 0.08% | +100.0% |
| Q1 2021 | $908,000 | -9.5% | 7,450 | +13.7% | 0.04% | -15.6% |
| Q4 2020 | $1,003,000 | +110.3% | 6,550 | +14.9% | 0.04% | +87.5% |
| Q3 2020 | $477,000 | +8.2% | 5,700 | -5.0% | 0.02% | -4.0% |
| Q2 2020 | $441,000 | -87.3% | 6,000 | -92.7% | 0.02% | -91.5% |
| Q1 2020 | $3,462,000 | +440.9% | 81,642 | +677.5% | 0.30% | +821.9% |
| Q4 2019 | $640,000 | +119.9% | 10,500 | +47.9% | 0.03% | +100.0% |
| Q3 2019 | $291,000 | -17.6% | 7,100 | -5.3% | 0.02% | -15.8% |
| Q2 2019 | $353,000 | – | 7,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |